Background illustration for clinical trials search

Skin Cancer Clinical Trials

Browse 473 skin cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

for
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma,
Location: Boston MA, New York NY, Chicago IL, Fargo ND,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 0 - 17

Code: NCT02332668

Phase1, Phase2, Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

for
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Location: Lebanon NH, Montreal, Camden NJ, Bethesda MD, Toronto,
Sponsor: Iovance Biotherapeutics, Inc.

Sex: All

Age: 18 - 70

Code: NCT05727904

Phase3, Recruiting

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

for
Recurrent Melanoma (Skin), Metastatic Melanoma,
Location: Philadelphia PA, Miami FL, Pittsburgh PA,
Sponsor: Perspective Therapeutics

Sex: All

Age: 18 - 70+

Code: NCT05655312

Phase1, Phase2, Recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

for
Uveal Melanoma
Location: Washington D.C. DC, Pittsburgh PA, Columbus OH,
Sponsor: Diwakar Davar

Sex: All

Age: 18+

Code: NCT06070012

Phase2, Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

for
Melanoma Stage IV, Solid Tumor
Location: Boston MA, New York NY, Richmond VA, Cincinnati OH,
Sponsor: Georgiamune Inc

Sex: All

Age: 18+

Code: NCT06425926

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

for
Melanoma Stage IIIB, Melanoma Stage IIIC, Melanoma Stage IIID
Location: Ney York NY, New Brunswick NJ, Philadelphia PA,
Sponsor: Philogen S.p.A.

Sex: All

Age: 18+

Code: NCT03567889

Phase3, Recruiting

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

for
Advanced Melanoma
Location: Hartford CT, Commack NY, Uniondale NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06594991

Phase2, Recruiting

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

for
Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC),
Location: North Haven CT, Lake Success NY, Chapel Hill NC,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06413680

Phase1, Phase2, Recruiting

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

for
Melanoma
Location: Maywood IL
Sponsor: Loyola University

Sex: All

Age: 18 - 70+

Code: NCT02870244

Phase1, Recruiting

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

for
Melanoma, Melanoma Stage III, Melanoma (Skin),
Location: Orange CA
Sponsor: University of California, Irvine

Sex: All

Age: 18+

Code: NCT06771544

Phase2, Recruiting

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

for
Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma
Location: Chapel Hill NC, Nashville TN, Denver CO
Sponsor: Iovance Biotherapeutics, Inc.

Sex: All

Age: 18 - 70

Code: NCT06940739

Phase1, Phase2, Recruiting

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

for
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor,
Location: Pittsburgh PA, Irvine CA
Sponsor: CJ Bioscience, Inc.

Sex: All

Age: 18+

Code: NCT05877430

Phase1, Phase2, Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

for
Unresectable Melanoma, Metastatic Melanoma,
Location: New York NY, Miami FL, Pittsburgh PA, Orlando FL,
Sponsor: Iovance Biotherapeutics, Inc.

Sex: All

Age: 18 - 70

Code: NCT05361174

Phase1, Phase2, Recruiting

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

for
Anemia, Iron Deficiency, Melanoma
Location: Indianapolis IN
Sponsor: Indiana University

Sex: All

Age: 18+

Code: NCT06508827

Phase2, Recruiting

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

for
Sinonasal Melanoma, Anorectal Melanoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT05546827

Phase2, Recruiting

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

for
Melanoma
Location: Louisville KY
Sponsor: University of Louisville

Sex: All

Age: 18+

Code: NCT01638676

Phase1, Phase2, Recruiting

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

for
Metastatic Uveal Melanoma
Location: New Hyde Park NY, Tampa FL, Chicago IL, Los Angeles CA
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT06121180

Phase2, Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

for
Advanced Melanoma
Location: Providence RI, Lebanon NH, Lake Success NY,
Sponsor: Replimune, Inc.

Sex: All

Age: 12+

Code: NCT06264180

Phase3, Recruiting

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

for
Metastatic Uveal Melanoma
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT07276386

Phase2, Recruiting

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

for
Melanoma
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 55+

Code: NCT07704918

Recruiting